Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hao Luo has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Yingli Wu

    Institute for Translational Medicine on Cell Fate and Disease, Shanghai Ninth People’s Hospital, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    7 shared publications
  • Hu Lei

    Department of Hematology, Tongren Hospital & Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of the National Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    4 shared publications
  • Peng Hao

    School of Basic Medical Sciences, Shandong Second Medical University, Weifang 261053, China

    4 shared publications
  • Jiale Wan

    School of Basic Medical Sciences, Shandong Second Medical University, Weifang 261053, China

    3 shared publications
  • Yunzhao Wu

    Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK

    3 shared publications
  • Zhenge Zhang

    Institute of Pharmaceutical Science, King's College London, London SE1 9NH, United Kingdom; Department of Hematology, Tongren Hospital & Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of the National Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

    3 shared publications

Latest Publications

  • Open Access

    The role of SAM-dependent internal m7G modification of LINC01252 in the progression of hepatocellular carcinoma

    by Xuehan Zhao, Min Shi, Li Zhao, Yingying Jiang, Wenying Zhang, Fan Liang, Hao Luo, Lintao Xian, Juan Feng, Yilei Yang, et al.

    Dysregulation of long non-coding RNAs (lncRNAs) plays a significant role in the progression of hepatocellular carcinoma (HCC), yet many underlying mechanisms remain elusive. Recent studies have highlighted the critical importance of internal N 7 -methylguanosine (m 7 G) modifications in influencing RNA expression and function. In this study, we identified LINC01252, a poorly characterized lncRNA, through analyses of GEO datasets and the TCGA cohort. Notably, LINC01252 is downregulated in HCC tissues and is associated with prognostic outcomes, although the predictive value of a nomogram based on LINC01252 expression characteristics appears to be limited. Our results indicate that LINC01252 effectively inhibits tumorigenic behaviors in HCC and exerts its effects by targeting the oncogene NUPR1. Mechanistically, LINC01252 acts as an intranuclear lncRNA that binds to the NUPR1 promoter through Hoogsteen pairing, consequently inhibiting its transcriptional activity. Additionally, the internal m 7 G modification level of LINC01252 directly influences its RNA stability, contingent upon sufficient concentrations of S-adenosylmethionine (SAM), which is necessary for the activity of its key modifying enzymes, METTL1 and WDR4. Thus, LINC01252’s m 7 G modification and expression are SAM-dependent in the context of HCC. Furthermore, LINC01252 can also suppress WDR4 transcription by binding to its promoter through the same mechanism, thus inhibiting HCC progression. Our findings suggest that LINC01252 functions as a SAM-dependent, m 7 G-related lncRNA, acting as a transcriptional repressor of NUPR1 and WDR4, while establishing a negative feedback loop between LINC01252 and WDR4. However, the potential of LINC01252 as a clinical biomarker still requires further investigation.

  • USP2 in cancer: a double-edged sword and therapeutic target

    by Peng Hao, Jiale Wan, Zhangyu Guo, Zhenge Zhang, Guoyun Hu, Yongkang Liu, Hu Lei, Yingli Wu, Hao Luo

  • Deubiquitinases in liver diseases: from mechanisms to targeted therapy

    by Zhenge Zhang, Wanli Duan, Yixiang Wang, Peng Hao, Linlin Chen, Ziyi Hao, Ming He, Yingli Wu, Hao Luo

    Fatty liver disease, hepatitis, hepatocellular carcinoma (HCC), and other major liver diseases are significant global public health challenges. A deeper understanding of the underlying mechanisms driving the onset and progression of these diseases, along with the exploration of potential targeted therapies, is of critical importance. The ubiquitin-proteasome system (UPS) plays a crucial role in protein degradation in eukaryotic cells. Deubiquitinases (DUBs) are key enzymes that regulate the balance between ubiquitination and deubiquitination, and they are involved in a wide range of cellular physiological processes. Dysregulation of DUBs is frequently observed in various liver diseases, including chronic liver diseases (CLDs) and HCC. Targeted therapies, with their high selectivity and low side effects, have attracted significant attention. Small molecules targeting DUBs have shown promising therapeutic effects in the treatment of major liver diseases. Given the important role of DUBs in liver diseases, this review focuses on summarizing the potential mechanisms through which DUBs contribute to the development of metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis, liver fibrosis, and HCC, as well as the application of DUB inhibitors. It aims to provide a theoretical foundation for basic research on major liver diseases and propose strategies for their treatment.


  • USP2 promotes metabolic dysfunction-associated steatotic liver disease progression via stabilization of PPARγ

    by Hao Luo, Chujiao Zhu, Yingying Wang, Yidong Dai, Peng Hao, Haiyan Cai, Wenhui Bai, Zhenge Zhang, Jiale Wan, Youping Zhang, et al.

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide, yet the molecular mechanisms underlying its pathogenesis are not fully understood. Here, we identify the deubiquitinating enzyme Ubiquitin-specific protease 2 (USP2) as a key regulator in hepatic lipid metabolism and MASLD progression. We show that USP2 expression is significantly upregulated in liver tissues from MASLD patients and high-fat diet (HFD)-induced mouse models. Usp2 knockout or pharmacological inhibition alleviates hepatic steatosis and improves systemic metabolic parameters both in vivo and in vitro. Strikingly, hepatocyte-targeted GalNAc-conjugated siRNA against Usp2 markedly attenuates MASLD in mouse models, highlighting therapeutic potential. Mechanistically, USP2 directly interacts with and stabilizes peroxisome proliferator-activated receptor γ (PPARγ) by removing K48-linked ubiquitin chains at lysine 161 within its DNA-binding domain, thereby preventing proteasomal degradation and enhancing its transcriptional activity. This USP2-PPARγ axis promotes hepatic lipid accumulation and drives MASLD progression. Our findings uncover a novel regulatory mechanism in MASLD pathogenesis and suggest that USP2 may represent a promising and druggable therapeutic target for metabolic liver disease.


  • Open Access

    USP24 stabilizes VDAC2 via deubiquitination to promote apoptosis and ferroptosis in clear cell renal cell carcinoma (ccRCC)

    by Peng Hao, Lingbo Xu, Linlin Chen, Jiale Wan, Xuanyu Ding, Yingli Wu, Hao Luo

    Objectives: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, and its pathogenesis is closely associated with dysregulated cell death. This study aims to elucidate the role of the ubiquitin-specific protease 24 (USP24) in ccRCC progression and its molecular mechanisms. Methods: Multi-omics data from the TCGA, GEO, and HPA databases were integrated to analyse USP24 expression levels and their clinical significance in ccRCC. The specific mechanism of interaction between USP24 and voltage-dependent anion channel 2 (VDAC2) was validated through co-immunoprecipitation, mass spectrometry analysis, molecular docking, and site-directed mutagenesis. In vitro functional assays – including deubiquitination assays, flow cytometry analysis of apoptosis, and assessment of ferroptosis-related markers – verified USP24’s inhibitory effect on ccRCC. Results: USP24 was significantly downregulated in ccRCC tissues and cell lines, with its low expression correlated with poor patient prognosis (hazard ratio [HR]=0.57, p<0.001), suggesting its potential utility as a prognostic indicator. Mechanistic studies revealed that USP24 directly binds VDAC2 and removes its ubiquitinylation at position 277, thereby stabilizing the VDAC2 protein. This stabilizing effect promotes apoptosis and ferroptosis in ccRCC cells, and reactivating this pathway may serve as a viable therapeutic strategy for ccRCC. Single-cell RNA sequencing analysis further confirmed the co-expression of USP24 and VDAC2 in renal tubular epithelial cells. Conclusions: This study reveals that the USP24-VDAC2 axis exerts key tumour-suppressive functions by promoting apoptosis and ferroptosis, thereby inhibiting ccRCC progression. Targeting this axis may provide novel therapeutic strategies for ccRCC.


  • Related cellular signaling and consequent pathophysiological outcomes of ubiquitin specific protease 24

    by Xiaoyang Song, Boyu Xia, Xinrong Gao, Xinying Liu, Hongyuan Lv, Shiwei Wang, Qinpei Xiao, Hao Luo


  • Ubiquitin Specific Protease 2: Structure,Isoforms,Cellular Function, Related Diseases and Its Inhibitors

    by Hao Luo, Yanjie Ji, Xinrong Gao, Xinying Liu, Yunzhao Wu, Yingli Wu

    The ubiquitin-proteasome system (UPS) is an important pathway for cellular protein degradation. The components of this pathway, including the proteasome, ubiquitinase, and deubiquitinase, are highly specialized and strictly regulated. The ubiquitin-specific protease 2 (USP2) belongs to the ubiquitin-specific proteases, a subgroup of deubiquitinating enzymes. USP2 plays essential roles in regulating cell survival, cell cycle, circadian rhythm, cell metabolism, inflammatory response, antiviral response, and metastasis by interacting with certain proteins such as Cyclin D1, PER1, CRY1, HDM2/p53, FASN, LDLR, TRAF6, TBK1, and TGFBR1-TGFBR2 complex. Elevation of USP2 has been observed in a variety of cancers, including glioma, testicular cancer, breast cancer, prostate cancer, and some inflammatory diseases. Moreover, USP2 also plays an important role in many non-neoplastic diseases. At present, there is no officially approved USP2 inhibitor in clinic. A few existing inhibitors targeting USP2 have shown certain effects in the treatment of colorectal cancer, but their mechanism of action and binding site information are not clear. Moreover, the efficacy and selection specificity need to be further optimized. The catalytic centers of USP family are relatively conserved, so the design of compounds targeting allosteric site is expected to improve the specificity and inhibitory activity. In this review, we summarize the latest advances of USP2 in its cellular function, related diseases, and small-molecule inhibitors targeting USP2.


  • Sinomenine can promote the proliferation and differentiation of osteoblasts by regulating the Akt/Runx2 signaling pathway in MC3T3-E1 cells

    by Bo Zhang, Haijun Zhang, Hao Luo, Chao Yang, Yi Yuan

    This study aimed to explore the effect of sinomenine on the proliferation and differentiation of MC3T3-E1 cells and the related mechanism. Mouse preosteoblastic cell line MC3T3-E1 cells were divided into four groups: control group, treatment of sinomenine with the concentrations of 100, 500 or 1000 μM. The proliferation and apoptosis of the cells were determined by MTT assay at 0, 24, 48 and 72 h, and flow cytometry method was used to determine the effect of sinomenine on the apoptosis of MC3T3-E1 cells at 72 h; furthermore, after 72 h, the cell culture supernatants were collected, and the levels of alkaline phosphatase and osteocalcin were examined by enzyme-linked immunosorbent assay (ELISA); next, cells were collected, and the expression of type I collagen (COL1A1), osteopontin (OPN), protein kinase B (Akt), runt-related transcription factor 2 (Runx2), B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax) were examined by RT-qPCR and Western Blot methods. It was observed that treatment of 500 and 1000 μM sinomenine has induced significant increase in the proliferation and decrease in the apoptosis of MC3T3-E1 cells; furthermore, sinomenine also lead to increased secretion of osteocalcin and alkaline phosphatase in MC3T3-E1 cells; finally, sinomenine induced marked increase in the expression of type I collagen, osteopontin and also induced the activation of the Akt/Runx2 signaling pathway. To sum up, we observed that sinomenine may promote the proliferation and differentiation of MC3T3-E1 cells via activating the Akt/Runx2 signaling pathway.


  • Open Access

    WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia

    by Hao Luo, Bo Jing, Yu Xia, Yugen Zhang, Meng Hu, Haiyan Cai, Yin Tong, Li Zhou, Li Yang, Junmei Yang, et al.

    T-cell acute lymphoblastic leukemia (T-ALL) is a lymphoid malignancy caused by the oncogenic transformation of immature T-cell progenitors with poor outcomes. WP1130 has shown potent activity against a variety of cancer but whether WP1130 has anti-T-ALL activity is not clear. USP24, one target of WP1130, is one of the largest deubiquitinases and its detailed mechanism is poorly understood. The aim of this study was to explore whether WP1130 could suppress T-ALL and the role of USP24 in T-ALL. Molecular docking and cellular thermal shift assay were performed to determine whether and how WP1130 directly interact with USP24. Mitochondrial transmembrane potential assay was measured via Rhodamine 123 staining. USP24 was reactivated using the deactivated CRISPR-associated protein 9 (dCas9)-synergistic activation mediator (SAM) system. The in vivo results were examined by tumor xenografts in NOD-SCID mice. All statistical analyses were performed with the SPSS software package. WP1130 treatment decreased the viability and induces apoptosis of T-ALL cells both in vitro and in vivo. Furthermore, we demonstrated that knockdown of USP24 but not USP9X could significantly induce growth inhibition and apoptosis of T-ALL cells. Oncomine database showed that USP24 expression was upregulated in T-ALL samples and Kaplan–Meier results indicated that the USP24 was negatively but USP9X was positively associated with survival in T-ALL patients. Additionally, we proposed that WP1130 directly interacts with the activity site pocket of USP24 in T-ALL cells, which leads to the decrease of its substrates Mcl-1. Mechanistically, WP1130 induces apoptosis by accelerating the collapse of mitochondrial transmembrane potential via USP24-Mcl-1 axis. Altogether, using WP1130 as a chemical probe, we demonstrate that USP24 but not USP9X is a novel target in T-ALL cells. Moreover, we uncovered that WP1130 induces apoptosis by accelerating the collapse of mitochondrial transmembrane potential via USP24-Mcl-1 axis. These results provide that USP24-Mcl-1 axis may represent a novel strategy in the treatment of T-ALL and WP1130 is a promising lead compound for developing anti-T-ALL drugs.


  • Open Access

    CDDO-Me reveals USP7 as a novel target in ovarian cancer cells

    by Dongjun Qin, Weiwei Wang, Hu Lei, Hao Luo, Haiyan Cai, Caixia Tang, Yunzhao Wu, Yingying Wang, Jin Jin, Weilie Xiao, et al.

    CDDO-Me reveals USP7 as a novel target in ovarian cancer cells CDDO-Me reveals USP7 as a novel target in ovarian cancer cells